Adapted Physical Activity Effect on Abilities & Quality of Life of

Status Completed

Clinical Trial Summary

Intro: Huntington's disease is a neurodegenerative disease that affects the brain, inducing a dysfunction and death of the middle spiny striatal projection neurons and a progressive alteration of cognitive and motor functions, and psycho-behavioral problems. There is currently no curative treatment but we know hat a multidisciplinary care can optimize the functioning and the quality of life of the patients with Huntington's disease. A meta-analysis of 18studies indicates that exercise and physical activity can improve motor function, gait speed and balance, and would also improve self-confidence, independence, well-being, reduced apathy and better socialization with family and friends. Hypothesis/Objective The hypothesis is that the inclusion of a 4 week-program with Adapted Physical Activity (APA) during a rehabilitation stay will improve some motor, cognitive and psycho-behavioral abilities, compared to the control group. Method The patients will be randomized into two groups : The control group will have the "classic" program performed in the standard of care with: kinesitherapy, soft gym, medico-social workshop, cognitive workshop, creative workshop, individual care (rehabilitation, rest, and creation). The experimental APA group will have in addition of the classic program, 6 APA workshops per week with collective support : Adapted Physical workshops, adapted cycling, therapeutic (horseback/equestrian) riding, cultural or leisure outings, situation tests For the two groups, at the start of the 4 weeks of rehabilitation program an initial visit will be performed with, as part of this research, a clinical examination, a neurological examination, a dietary consultation, as well as a biological assessment as part of habitual care. The clinical examination, the neurological examination and the dietary consultation will be performed each week, during the 4 weeks of the program, At the end of the study, one month after the rehabilitation of the patient, a visit by phone-call will be performed for the patient and his caregiver.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Huntington Disease

Clinical Trial Details

NCT number	NCT04917133
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact
Status	Completed
Phase	N/A
Start date	June 7, 2021
Completion date	December 7, 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03052712` - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies	N/A
Not yet recruiting	`NCT04429230` - Non-invasive Brain Stimulation in Huntington's Disease	N/A
Recruiting	`NCT05032196` - Study of WVE-003 in Patients With Huntington's Disease	Phase 1/Phase 2
Recruiting	`NCT03599076` - Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
Terminated	`NCT04617860` - Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease	Phase 1/Phase 2
Completed	`NCT05748288` - Development of the Virtual Unified Huntington's Disease Rating Scale
Not yet recruiting	`NCT05360082` - Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
Not yet recruiting	`NCT04370470` - Development of Assessments for Later Stage HD
Recruiting	`NCT01834053` - Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.	Phase 1/Phase 2
Completed	`NCT01357681` - Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)	Phase 2
Completed	`NCT01458470` - A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease	Phase 2
Completed	`NCT00980694` - Bioavailability of Ubiquinol in Huntington Disease	Phase 1
Completed	`NCT00146211` - TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease	Phase 3
Recruiting	`NCT01412125` - Study of Biomarkers That Predict the Evolution of Huntington's Disease	N/A
Completed	`NCT00075140` - Family Health After Predictive Huntington Disease (HD) Testing	Phase 3
Recruiting	`NCT04818060` - Preparing for Prevention of Huntington's Disease (PREVENT-HD)
Active, not recruiting	`NCT04698551` - NIPD on cffDNA for Triplet Repeat Diseases
Not yet recruiting	`NCT04301726` - Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD	Phase 1
Completed	`NCT03421327` - Genetic Risk: Whether, When, and How to Tell Adolescents
Recruiting	`NCT03296176` - Metabolomic Study in Huntington's Disease (METABO-HD)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Adapted Physical Activity Effect on Abilities and Quality of Life of Huntington Patients and Relatives During Rehab Stay — HUNT'ACTIV

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms